Oleander Medical Technologies was founded with the mission to innovate revolutionary cancer treatments, focusing on combating the most invasive and deadly types. The company's core product, Targeted Osmotic Lysis (TOL), leverages the unique properties of malignant cancer cells to selectively destroy them. By exploiting how sodium channels in these cells respond to disease, Oleander aims to provide a highly effective and targeted cancer treatment. Their market focus is on developing cutting-edge medical technologies that offer new hope for patients with aggressive cancers.
Key figures affiliated with Oleander Medical Technologies include Dr. Dennis Paul and Dr. Harry Gould from Louisiana State University, whose research on cell function and sodium channels underpins the TOL technology. The company has garnered attention for its innovative approach, although specific investors and detailed achievements have not been disclosed. Oleander's impact lies in its potential to transform cancer treatment paradigms, offering a novel solution that could significantly improve patient outcomes for some of the most challenging cancer types.
Oleander Medical Technologies' most recent funding round was for $150k (USD) in February 2017.
As of Feb 13, 2017, Oleander Medical Technologies has disclosed funding of $4.6M (USD).

Phoenix Biotechnology
Nerium Biotechnology
nbiresearch.com

Oncolyze
oncolyze.com

SonALAsense
sonalasense.com

Candesant Biomedical
candesant.com

Telo Therapeutics

Oleolive
oleo.live

Onchilles Pharma

Novocure
novocure.com

Centrose
centrosepharma.com

Oncology Honduras

Autem Therapeutics
Oncolix

Gradient Medical
Tau Therapeutics

On Target Laboratories

Bio-Path Holdings

Akanocure Pharmaceuticals
akanocure.com

Advanced Chemotherapy Technologies

Ostentus Therapeutics